Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial
Open Access
- 10 March 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 4 (3) , e001349
Abstract
Background: In the ROCKET AF (Rivaroxaban–Once‐daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual patient time in the therapeutic range ( iTTR ) of the international normalized ratio ( INR ), were associated with longer inter‐ INR test intervals. The standard R osendaal approach can produce biased low estimates of TTR after an appropriate dose change if the follow‐up INR test interval is prolonged. We explored the effect of alternative calculations of TTR that more immediately account for dose changes on regional differences in mean iTTR in the ROCKET AF trial. Methods and Results: We used an INR imputation method that accounts for dose change. We compared group mean iTTR values between our dose change–based method with the standard R osendaal method and determined that the differences between approaches depended on the balance of dose changes that produced in‐range INR s (“corrections”) versus INR s that were out of range in the opposite direction (“overshoots”). In ROCKET AF , the overall mean iTTR of 55.2% (Rosendaal) increased up to 3.1% by using the dose change–based approach, depending on assumptions. However, large inter‐regional differences in anticoagulation control persisted. Conclusions: TTR , the standard measure of control of warfarin anticoagulation, depends on imputing daily INR values for the vast majority of follow‐up days. Our TTR calculation method may better reflect the impact of warfarin dose changes than the Rosendaal approach. In the ROCKET AF trial, this dose change–based approach led to a modest increase in overall mean iTTR but did not materially affect the large inter‐regional differences previously reported. Clinical Trial Registration: URL: ClinicalTrials.gov. Unique identifier: NCT00403767.Keywords
This publication has 23 references indexed in Scilit:
- Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical TrialJournal of the American Heart Association, 2013
- National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011Circulation: Cardiovascular Quality and Outcomes, 2012
- Antithrombotic Therapy for Atrial FibrillationChest, 2012
- Oral Anticoagulant TherapyChest, 2012
- Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculAEuropean Heart Journal, 2011
- Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral AnticoagulationCirculation: Cardiovascular Quality and Outcomes, 2011
- Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?Circulation: Cardiovascular Quality and Outcomes, 2009
- The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumonThrombosis Research, 2008
- Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic RangeCirculation, 2008
- WarfarinNew England Journal of Medicine, 1984